Trading Signals: VIR Stock Price Prediction and Forecast (Fri. Oct. 11, 2019 - Fri. Dec. 22, 2023)(Vir Biotechnology, Inc. )
| VIR latest price $10.0350 (0.25%) ($10.0350 - $10.0350) on Thu. Sep. 14, 2023. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 6.13% (three month average) | RSI | 8 | Latest Price | $10.0350(0.25%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | VIR declines -2.8% a day on average for past five trading days. | Weekly Trend | VIR declines -10.2% a week on average for past two weeks. | Market Behavior | Broad based rally for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support VIR advance at 0% a week (0% probability) XBI(66%) ARKG(65%) IBB(64%) IWO(64%) IWM(63%) | Factors Impacting VIR price | VIR will decline at least -3.065% in a week (0% probabilities). TBT(-29%) VXX(-21%) UUP(-18%) VIXM(-15%) URA(1%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -3.065% (StdDev 6.13%) | Hourly BBV | -1.1 () | Intraday Trend | 0% | | | |
|
1 - 5 Day Possible Target | $-4.6(-145.84%) | Resistance Level | $12.03 | 5 Day Moving Average | $10.45(-3.97%) | 10 Day Moving Average | $11.27(-10.96%) | 20 Day Moving Average | $12.03(-16.58%) | To recent high | -61.4% | To recent low | 0.2% | Market Cap | $1.181b | | | | Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The firm's technology platforms include antibody, T cell, innate immunity and siRNA, which are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. The company was founded by Robert Taylor Nelsen, Klaus Frueh, Jay Parrish, Lawrence Corey, and Louis Picker in April 7, 2016 and is headquartered in San Francisco, CA.April 6, 2020 Vir Biotechnology is adding GlaxoSmithKline to its roster of COVID-19 partners—and snagging a $250 million investment in the process. The duo will pool their resources to develop vaccines and treatments for coronaviruses, starting with two antibodies against SARS-CoV-2, the virus behind the current pandemic, which could hit phase 2 studies as early as this summer. |